http://orcid.org/0000-0003-0491-4689
References
- Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol. 2016;3:e163–e175.
- Abarca M, Andrade RJ, García-Arjona A, et al. CASE REPORT: portal hypertension and refractory ascites associated with multicentric Castleman’s disease. Dig Dis Sci. 2000;45:697–702.
- Hartleb M, Gutkowski K, Milkiewicz P. Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension. WJG. 2011;17:1400–1409.
- Kiyuna A, Sunagawa T, Hokama A, et al. Nodular regenerative hyperplasia of the liver and Castleman’s disease: potential role of interleukin-6. Dig Dis Sci. 2005;50:314–316.
- Molina T, Delmer A, LeTourneau A, et al. Hepatic lesions of vascular origin in multicentric Castleman’s disease, plasma cell type: report of one case with peliosis hepatis and another with perisinusoidal fibrosis and nodular regenerative hyperplasia. Pathol Res Pract. 1995;191:1159–1164.
- Dispenzieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of Castleman’s disease. Am J Hematol. 2012;87:997–1002.
- Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014;123:2924–2933.
- Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998;128:657–662.
- National Comprehensive Cancer Network. B-cell lymphomas (Version 3. 2017). [cited 2017 June 10]. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
- Van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15:966–974.
- Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood. 1989;74:1360–1367.
- Maione D, Di Carlo E, Li W, et al. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EBMO J. 1998;17:5588–5597.